Brii Biosciences Limited (02137.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.0x

Market Cap

HKD 671.34M

MomentumView details →

1D Return

+2.20%

YTD Return

−34.04%

RSI (14)

42.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.0x

Market Cap

HKD 671.34M

RSI (14)

42.5

MomentumView details →

1D Return

+2.20%

YTD Return

−34.04%

ProfitabilityView details →

Gross Margin

86.86%

Net Margin

−1057.33%

EBITDA Margin

−1195.15%

ROE (TTM)

−24.54%

ROA (TTM)

−24.72%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

−70.26%

EPS YoY

+7.30%

FCF YoY

+66.06%

Revenue CAGR 3Y

−29.46%

EPS CAGR 3Y

+57.14%

EBITDA YoY

+33.10%

EarningsView details →

EPS (Actual)

−HKD 0.16

EPS Surprise

−47.00%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−47.00%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

52.24x

Quick Ratio

52.24x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

51.42M

Net Income (TTM)

−543.66M

Op. CF (TTM)

−457.38M

Next earningsMar 19, 2027 →

Latest newsMore news →

Brii Biosciences reported its interim results for the six months ended June 2026, with a narrowed net loss attributable to shareholders of RMB 101 million, compared to a loss of RMB 148 million in the same period last year, and no interim dividend declared.15d ago

Similar companies

Prime Medicine, Inc.PRME BlossomHill Therapeutics, Inc.BLSM MiMedx Group, Inc.MDXG Altimmune, Inc.ALT Sagimet Biosciences Inc.SGMT Allogene Therapeutics, Inc.ALLO Find similar companies →

Latest newsMore news →

Brii Biosciences reported its interim results for the six months ended June 2026, with a narrowed net loss attributable to shareholders of RMB 101 million, compared to a loss of RMB 148 million in the same period last year, and no interim dividend declared.15d ago